1xbet 신청 Pharmaceutical Co., Ltd.

1xbet 신청 Pharmaceutical Co., Ltd. announces that it has received regulatory approval in Japan for the additional indication of suppression of recurrence and relapse of mood episodes in bipolar I disorder for ABILIFY MAINTENA (aripiprazole), a long-acting injectable suspension. The approved indication covers the 300 mg and 400 mg vials (for injection) and the 300 mg and 400 mg dual-chamber syringes.

ABILIFY MA1xbet 신청TENA is a depot preparation for 1xbet 신청tramuscular 1xbet 신청jection that adm1xbet 신청istered monthly as a s1xbet 신청gle 1xbet 신청jection.

1xbet 신청 Pharmaceutical discovered ABILFY MAINTENA, an atypical antipsychotic, which first received regulatory approval in 2013 in the U.S. and E.U. for the treatment of adult schizophrenia. In 2015, it was approved in Japan for the same indication. In the U.S. and Canada, the indication as maintenance therapy for adult bipolar I maintenance therapy was added in 2017.